This study reports two unique TCRs against the PIK3CAN345K gene product, encoded by the 5th most common PIK3CA mutation, comprising 3% of all PIK3CA missense mutations, and is expressed in approximately 0.38% of all patients with advanced cancer [8]. This evidence concerns the gene PIK3CA and cancer.